1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECGP60474Cat. No.: HY-11009CAS No.: 164658-13-3分式: CHClNO分量: 355.82作靶點: VEGFR; PKC作通路: Protein Tyrosine Kinase/RTK; Epigenetics; TGF-beta/Smad儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO :

2、50 mg/mL (140.52 mM)H2O : 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (7.03 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (7.03 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 CGP60474種有效的 VEGFR-2 抑制劑，IC50 值為 84 nM，同

3、時為 ATP-競爭性的 PKC 抑制劑。IC50 & Target VEGFR-2 PKC84 nM (IC50)體外研究 CGP60474 (Compound A) is a potent VEGFR-2 inhibitor, with an IC50 of 84 nM 1. CGP60474 is also aPKC inhibitor, with competitive kinetics relative to ATP 2.戶使本產品發表的科研獻 Sci Rep. 2018 Oct 8;8(1):14969. Oncotarget. 2017 Nov 22;8(65):109135-10

4、9150. Harvard Medical School LINCS LIBRARYSee more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Kuo GH, et al. Synthesis and identification of 1,3,5triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinaseinhibitors. J Med Chem. 2005 Jul 14;48(14):4535-46.2.

5、Stanetty P, et al. Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-couplingstrategy. J Org Chem. 2005 Jun 24;70(13):5215-20.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-5895